OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
September 02, 2022
This article introduces the requirements for a biosimilar license in Brazil and addresses questions about their quality, safety, and efficacy.
August 23, 2022
The European Commission (EC) has approved Celltrion Healthcare's Vegzelma (CT-P16), a biosimilar to bevacizumab referencing Avastin.
July 02, 2022
The business impact of modeling and simulation tools is not well understood and requires clarification of their benefits to drug development.
June 01, 2022
Linking structure with function is paramount.
January 28, 2022
Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.
November 12, 2021
The Democratic legislative proposal to authorize price negotiations on costly medicines covered by Medicare has drawn opposition from brand pharmaceutical and biotech companies.
November 01, 2021
The biopharmaceutical landscape of India is transforming in terms of regulatory policies, product development, and affordability.
October 15, 2021
The evolution of regulatory guidelines for biosimilars alongside improvements in knowledge and understanding provide a platform for growth in the European market.
October 01, 2021
Establishing bioassay studies for biosimilar development is important for supporting regulatory filings.
September 27, 2021
Biosimilar approvals and the advance of biosimilar testing and production may lead to greater access to alternative therapies.